Sugi Predict

Sugi Predict / Targets / CSK

CSK

Tyrosine-protein kinase CSK · P41240 · CSK on Sugi Atlas →

36,445 patent compounds predicted against CSK, 31,732 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL173288 SCHEMBL173288 1.00 3/20
SCHEMBL371886 SCHEMBL371886 0.60 3/20
SCHEMBL129862 SCHEMBL129862 0.57 3/20
SCHEMBL129870 SCHEMBL129870 0.56 3/20
SCHEMBL372007 SCHEMBL372007 0.56 3/20
SCHEMBL372225 SCHEMBL372225 0.56 3/20
SCHEMBL371939 SCHEMBL371939 0.55 3/20
SCHEMBL372271 SCHEMBL372271 0.55 3/20
SCHEMBL168790 SCHEMBL168790 0.51 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL173736) 0.50 3/20
SCHEMBL173597 SCHEMBL173597 0.47 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL173601) 0.46 3/20
Saracatinib Saracatinib (SCHEMBL41547) 1.00 2/20
SCHEMBL201744 SCHEMBL201744 1.00 2/20
SCHEMBL201745 SCHEMBL201745 1.00 2/20
SCHEMBL371758 SCHEMBL371758 0.87 2/20
SCHEMBL371897 SCHEMBL371897 0.82 2/20
SCHEMBL202187 SCHEMBL202187 0.81 2/20
SCHEMBL372005 SCHEMBL372005 0.73 2/20
SCHEMBL372006 SCHEMBL372006 0.73 2/20

Clinical trials — most relevant to CSK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate PHASE2/PHASE3WITHDRAWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy PHASE2COMPLETED
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer PHASE2COMPLETED
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. PHASE1/PHASE2UNKNOWN
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients PHASE2COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma PHASE2ACTIVE_NOT_RECRUITING
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer PHASE2RECRUITING
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib PHASE2COMPLETED
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Phase II Dasatinib Study in Advanced Breast Cancer PHASE2COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1ACTIVE_NOT_RECRUITING
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases nanCOMPLETED
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) nanWITHDRAWN
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CSK binder may also engage these)

ProteinNameSimilarity
P41241 — 1.000 P41241 →
Q0VBZ0 — 1.000 Q0VBZ0 →
P32577 — 1.000 P32577 →
P41239 — 1.000 P41239 →
TXK Tyrosine-protein kinase TXK 0.995 landscape →
ITK Tyrosine-protein kinase ITK/TSK 0.994 landscape →
FRK Tyrosine-protein kinase FRK 0.994 landscape →
P42690 — 0.994 P42690 →
P42682 — 0.993 P42682 →
Q64434 — 0.993 Q64434 →
Q9V9J3 — 0.991 Q9V9J3 →
P00528 — 0.990 P00528 →
PTK6 Protein-tyrosine kinase 6 0.990 landscape →
P00526 — 0.990 P00526 →
P35991 — 0.989 P35991 →
P42686 — 0.989 P42686 →
TEC Tyrosine-protein kinase Tec 0.989 landscape →
P63185 — 0.988 P63185 →
Q62662 — 0.988 Q62662 →
Q922K9 — 0.987 Q922K9 →
P24604 — 0.987 P24604 →
P17713 — 0.987 P17713 →
BTK Tyrosine-protein kinase BTK 0.987 landscape →
Q8JH64 — 0.987 Q8JH64 →
P31693 — 0.987 P31693 →
G5EE56 — 0.986 G5EE56 →
O45539 — 0.986 O45539 →
P10447 — 0.985 P10447 →
FGR Tyrosine-protein kinase Fgr 0.985 landscape →
P25020 — 0.985 P25020 →